Herbalife acquires Bioniq for £120m; China's energy drink market surges to £2.4bn
Herbalife's acquisition of UK-based Bioniq for up to £120 million signals aggressive expansion into personalised nutrition, while China's energy and sports drink market demonstrates robust 31.8% year-on-year growth.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 07 April 2026
Herbalife Ltd. has acquired the assets of Bioniq, a UK-based personalised supplements company, in a deal valued at up to $150 million (£120 million). This strategic move expands Herbalife’s tailored nutrition portfolio, leveraging Bioniq's science-driven platform for global scalability across Herbalife’s 95 markets. Stephan Gratziani, Herbalife’s CEO, highlighted the increasing demand for personalised, data-informed wellness solutions. The acquisition integrates Bioniq’s technology with Herbalife’s existing infrastructure, including Pro2col, to deliver individualised supplements. This deal demonstrates a significant investment in the personalized nutrition sector and indicates a potential consolidation trend among larger players seeking to enhance bespoke product offerings.
Concurrently, the US Food and Drug Administration (FDA) held a public meeting to scrutinise the definition of 'dietary substance' within its regulatory framework for dietary supplements. Discussions focused on whether the definition should remain confined to ingredients already in the food supply or expand to include novel substances resulting from advancements like plant cell culture and precision fermentation. Industry representatives advocate for broader interpretations to accommodate scientific innovation, while consumer groups like CSPI express caution regarding potential risks. Kyle Diamantas, FDA’s Deputy Commissioner for Human Foods, acknowledged that the regulatory framework, largely unchanged since DSHEA, must adapt to over 30 years of industry growth and innovation. The outcome of these deliberations could significantly alter the path for novel ingredients entering the US market, with potential ripple effects on global ingredient development and regulatory harmonisation.
In China, Eastroc Beverage reported a 31.8% revenue increase in 2025, reaching RMB20.9 billion (approximately £2.4 billion), driven by robust demand for energy and sports drinks. Energy beverages, spearheaded by Eastroc Super Drink, constituted nearly 75% of this revenue with a 17.3% growth. Sports drinks, notably Eastroc Water Boost, surged by 119%. This growth reflects a shift from occasional use to habitual consumption of functional beverages, attributed to Eastroc’s strategy of combining strong functional claims with competitive pricing. The expanding appeal of sports drinks beyond athletes to a broader consumer base, driven by benefits such as 'rapid electrolyte replenishment', underscores a significant opportunity in the Chinese functional beverage market.
What this means for United Kingdom
UK personalised nutrition brand owners must ready for increased M&A activity, with potentially elevated valuations due to consolidation pressures post-Bioniq acquisition. Regulatory teams should closely monitor FDA discussions on 'dietary substance' definitions; a relaxed interpretation could streamline novel ingredient development, while stricter adherence may impede innovative ingredient R&D affecting UK export potential. Brand owners eyeing the Chinese market should consider localising functional beverage formulations to capitalise on the 31.8% market growth seen in 2025, especially focusing on accessible pricing and clear functional claims popularised by brands like Eastroc Beverage. This presents a competitive opportunity for UK firms with strong R&D in functional ingredients.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.